Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2022

Open Access 01-12-2022 | Comment

RETRACTED ARTICLE: Association of cord blood asprosin concentration with atherogenic lipid profile and anthropometric indices

Authors: Hanan Khudhair Hussein, Nassrin Malik Aubead, Hamzah H. Kzar, Yasir Salam Karim, Ali H. Amin, Moaed E. Al-Gazally, Tousief Irshad Ahmed, Mohammed Abed Jawad, Ali Thaeer Hammid, Abduladheem Turki Jalil, Yasser Fakri Mustafa, Marwan Mahmood Saleh, Hafez Heydari

Published in: Diabetology & Metabolic Syndrome | Issue 1/2022

Login to get access

Abstract

Background

Elevated lipids in umbilical cord blood affect fetal programming, leading to a higher risk of developing cardiovascular disease in later life. However, the causes of changes in the lipid profile of umbilical cord blood are not clear yet. This study aimed for the first time to determine the association of asprosin concentration with TAG, TC, HDL-C, LDL-C concentrations and TAG/HDL-C, TC/HDL-C, LDL-C/HDL-C and non-HDL-C/HDL-C ratio in umbilical cord blood as well as newborn anthropometric indices. This cross-sectional study was based on 450 mother- newborn pairs of a birth cohort study in Sabzevar, Iran. Multiple linear regression was used to estimate the association of lipid concentration and lipid ratios as well as birth weight (BW), birth length (BL), head circumference (HC) and chest circumference (CC) with asprosin in cord blood samples controlled for the relevant covariates.

Result

In fully adjusted models, each 1 ng/mL increase in asprosin was associated with 0.19 (95% CI 0.06, 0.31, P < 0.01), 0.19 (95% CI 0.10, 0.29, P < 0.01), 0.17 (95% CI 0.09, 0.25, P < 0.01), 0.17 (95% CI 0.09, 0.25, P < 0.01), 0.01 (95% CI 0.00, 0.013, P < 0.01), 0.01 (95% CI 0.01, 0.01, P < 0.01), 0.01 (95% CI 0.01, 0.01, P < 0.01) and 0.01 (95% CI 0.01, 0.01, P < 0.01) increase in TAG, TC, LDL-C, TAG/HDL-C, TC/HDL-C, LDL-C/HDL-C and non-HDL-C/HDL-C ratio respectively. Moreover, higher asprosin levels was positively associated with newborn BW, BL, HC and CC; however, these associations were not statistically significant.

Conclusion

Overall, our findings support the positive association between cord asprosin concentration and the development of atherogenic lipid profile in newborns. Further studies are needed to confirm the findings of this study in other populations.
Literature
1.
Benjamin EJ. Correction to: heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e646.CrossRef
2.
Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118(4):535–46.PubMedCrossRef
3.
Salari A, Roshanaei K, Rasoulian B, Khalili Fard J. Carvacrol attenuates disrupted lipid profile induced by organophosphates in male wistar rat: a comparative toxicity. J Chem Health Risks. 2021;11((Special Issue: Bioactive Compounds: Their Role in the Prevention and Treatment of Diseases)):121–8.
4.
Napoli C, D’Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100(11):2680–90.PubMedPubMedCentralCrossRef
5.
Casanueva V, Cid X, Chiang M, Molina M, Ferrada M, Perez R, et al. Lipids, lipoproteins and apolipoproteins in normal newborns. Rev Med Chil. 1998;126(9):1073–8.PubMed
6.
Nelson SM, Freeman DJ, Sattar N, Johnstone FD, Lindsay RS. IGF-1 and leptin associate with fetal HDL cholesterol at birth: examination in offspring of mothers with type 1 diabetes. Diabetes. 2007;56(11):2705–9.PubMedCrossRef
7.
Fonseca MJ, Santos AC. Umbilical cord blood adipokines and newborn weight change. Arch Gynecol Obstet. 2015;291(5):1037–40.PubMedCrossRef
8.
Xiao-yun C. A study of changes of leptin, cholesterol and triglyceride in cord blood of newborns. J Taishan Med Coll. 2008;10.
9.
Kelishadi R, Badiee Z, Adeli K. Cord blood lipid profile and associated factors: baseline data of a birth cohort study. Paediatr Perinat Epidemiol. 2007;21(6):518–24.PubMedCrossRef
10.
11.
Sowndarya K, Joseph JA, Shenoy A, Hegde A. Evaluation of triglyceride/high-density lipoprotein ratio as a surrogate marker for insulin resistance in healthy young males. J Nat Sci Biol Med. 2021;12:213.CrossRef
12.
Vaccaro C, Shakeri A, Czaplinski E, Eltonsy S. New-generation antiepileptic drugs during pregnancy and the risk of attention-deficit hyperactivity disorder: a scoping review. J Popul Ther Clin Pharmacol. 2020;27(4):e1–18.PubMedCrossRef
13.
Nakhaei P, Margiana R, Bokov DO, Abdelbasset WK, Kouhbanani MAJ, Varma RS, et al. Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol. Front Bioeng Biotechnol. 2021;9:705886.PubMedPubMedCentralCrossRef
14.
Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566–79.PubMedPubMedCentralCrossRef
15.
Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183–8.PubMedCrossRef
16.
Long W, Xie X, Du C, Zhao Y, Zhang C, Zhan D, et al. Decreased circulating levels of asprosin in obese children. Horm Res Paediatr. 2019;91(4):271–7.PubMedCrossRef
17.
Rerksuppaphol L, Rerksuppaphol S. Comparison of equations for the calculation of low-density lipoprotein cholesterol in thai population. J Nat Sci Biol Med. 2021;12:224.CrossRef
18.
j Manna M, Jabur MS. The value of lisnopril in managing impaired fertility in experimental rats following alloxan induced hyperglycemia. J Pharm Negat Results. 2022;12(2):18.
19.
20.
Wang Y, Qu H, Xiong X, Qiu Y, Liao Y, Chen Y, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm. 2018;2018:9471583.PubMedPubMedCentralCrossRef
21.
Li X, Liao M, Shen R, Zhang L, Hu H, Wu J, et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm. 2018;2018:7375294.PubMedPubMedCentralCrossRef
22.
Ghiasi A, Ziaee S, Faghihzadeh S. A Comparison of lipid and lipoprotein B-100 (Apo B-100) Levels in the umbilical cord blood of male and female newborns and the assessment of their impact on neonatal anthropometric indices. Pathobiol Res. 2013;16(1):55–62.
23.
Jahanfar S, Lim K. The impact of gender on anthropometric measures of twins. Twin Res Hum Genet. 2016;19(6):652–8.PubMedCrossRef
24.
Hoffmann T, Morcos YAT, Janoschek R, Turnwald E-M, Gerken A, Müller A, et al. Correlation of metabolic characteristics with maternal, fetal and placental asprosin in human pregnancy. Endocr Connect. 2022;11(3): e220069.PubMedPubMedCentralCrossRef
25.
Alan M, Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan I, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35(3):220–3.PubMedCrossRef
26.
Jung TW, Kim HC, Kim HU, Park T, Park J, Kim U, et al. Asprosin attenuates insulin signaling pathway through PKCdelta-activated ER stress and inflammation in skeletal muscle. J Cell Physiol. 2019;234(11):20888–99.PubMedCrossRef
27.
Pawitan JA, Leviana M, Sukmawati D, Liem IK, Margiana R, Tarcisia T. Prospect of umbilical cord mesenchymal stem cell culture waste in regenerative medicine. J Global Pharma Technol. 2017;9(7):1–5.
28.
Margiana R, Jusuf AA, Lestari SW. Immunohistochemistry Detection Method of Rejection Reaction of Human Umbilical Cord Derived Mesenchymal Stem Cell on Rat Sciatic Nerve Tissue. 2009.
29.
Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S135–48.PubMedCrossRef
30.
Kalvisa A, Siersbaek MS, Praestholm SM, Christensen LJL, Nielsen R, Stohr O, et al. Insulin signaling and reduced glucocorticoid receptor activity attenuate postprandial gene expression in liver. PLoS Biol. 2018;16(12): e2006249.PubMedPubMedCentralCrossRef
31.
Liu Y, Nakagawa Y, Wang Y, Liu L, Du H, Wang W, et al. Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice. J Mol Endocrinol. 2008;41(2):53–64.PubMedPubMedCentralCrossRef
32.
Ahmad K. Insulin sources and types: a review of insulin in terms of its mode on diabetes mellitus. J Tradit Chin Med. 2014;34(2):234–7.PubMedCrossRef
33.
Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J. 2002;366(Pt 2):377–91.PubMedPubMedCentralCrossRef
34.
35.
Santoleri D, Titchenell PM. Resolving the paradox of hepatic insulin resistance. Cell Mol Gastroenterol Hepatol. 2019;7(2):447–56.PubMedCrossRef
36.
37.
Bahrebar M, Edalatpanah Y. The effect of consumption the alcoholic extract of cedar on blood glucose, urea and total cholesterol diabetic rats. J Chem Health Risks. 2021;11((Special Issue: Bioactive Compounds: Their Role in the Prevention and Treatment of Diseases)):93–7.
38.
Wang M, Yin C, Wang L, Liu Y, Li H, Li M, et al. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab. 2019;75(4):205–12.PubMedCrossRef
39.
Groener JB, Valkanou A, Kender Z, Pfeiffenberger J, Kihm L, Fleming T, et al. Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PLoS ONE. 2019;14(9): e0222771.PubMedPubMedCentralCrossRef
40.
Zhang X, Jiang H, Ma X, Wu H. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig. 2019;11(12):349–55.PubMedPubMedCentral
41.
Pradhan MR, Patel SK, Patel S. Risk Factors and spatial clustering of primary infertility in India. J Infertil Reprod Biol. 2021;9(1):27–34.
42.
Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96–104.PubMedCrossRef
43.
Millington GW. The role of proopiomelanocortin (POMC) neurones in feeding behaviour. Nutr Metab. 2007;4:18.CrossRef
44.
Mori Y. Regulation of appetite by melanocortin and its receptors. Nihon Rinsho Japanese J Clin Med. 2001;59(3):431–6.
45.
Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, et al. The central melanocortin system directly controls peripheral lipid metabolism. J Clin Investig. 2007;117(11):3475–88.PubMedPubMedCentralCrossRef
46.
Albarado DC, McClaine J, Stephens JM, Mynatt RL, Ye J, Bannon AW, et al. Impaired coordination of nutrient intake and substrate oxidation in melanocortin-4 receptor knockout mice. Endocrinology. 2004;145(1):243–52.PubMedCrossRef
Metadata
Title
RETRACTED ARTICLE: Association of cord blood asprosin concentration with atherogenic lipid profile and anthropometric indices
Authors
Hanan Khudhair Hussein
Nassrin Malik Aubead
Hamzah H. Kzar
Yasir Salam Karim
Ali H. Amin
Moaed E. Al-Gazally
Tousief Irshad Ahmed
Mohammed Abed Jawad
Ali Thaeer Hammid
Abduladheem Turki Jalil
Yasser Fakri Mustafa
Marwan Mahmood Saleh
Hafez Heydari
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2022
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-022-00844-7

Other articles of this Issue 1/2022

Diabetology & Metabolic Syndrome 1/2022 Go to the issue

Research

Diagnostic significance of serum FGD5-AS1 and its predictive value for the development of cardiovascular diseases in patients with type 2 diabetes

Research

Identification of genetic variants related to metabolic syndrome by next-generation sequencing

Research

Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report

Research

Understanding reasons and factors for participation and non-participation to a medication adherence program for patients with diabetic kidney disease in Switzerland: a mixed methods study

Research

Fibrinogen function indexes are potential biomarkers of diabetic peripheral neuropathy

Research

Insight into the hepatoprotective, hypolipidemic, and antidiabetic impacts of aliskiren in streptozotocin-induced diabetic liver disease in mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits